The Toronto and Dallas-based firm, which trades under the ticker PINK on the TSX Venture Exchange and PYNKF on the OTCQX, is currently focused on the rollout of its Claire OCT system. The device, recently granted FDA approval, utilizes ultra-high-resolution, real-time imaging combined with AI-enabled algorithms to assist surgeons in identifying suspicious focal areas during breast cancer lumpectomies.

Management is also facilitating one-on-one investor meetings throughout the event for those registered to attend. The Claire system acts as an adjunctive tool intended for use alongside standard histopathology, specifically designed for patients with biopsy-confirmed breast cancer. It does not replace traditional diagnostic methods and carries strict usage limitations, including exclusions for patients with metastatic disease, those under 18, or individuals with specific prior surgical histories. Detailed safety information is available through the company’s official prescriber labeling.